Amani Upendo Wellness: Empowering Families Through Peace and Love
United States, June 29, 2025 -- A Transformative Approach to Wellness: Amani Upendo Wellness
In today's fast-paced world, wellness often seems like a luxury, something people can only experience once they have time to focus on themselves. For Gloria, the founder of Amani Upendo Wellness, this notion couldn't be further from the truth. She believes that wellness is about more than just physical health—it's about emotional, spiritual, and familial well-being. Through her work as a Wellness & Trauma-Informed Coach, she is on a mission to help people heal from within and reclaim their stories.
Wellness Rooted in Peace and Love
The name of the company itself speaks to its core philosophy. 'Amani' means peace and 'Upendo' means love in Swahili, and these ideals form the bedrock of the services and outreach that Amani Upendo Wellness offers. Gloria's approach to wellness coaching isn't just a job—it's a calling. Every interaction, whether it's through one-on-one coaching or community outreach, is rooted in these values, allowing individuals and families to experience profound transformation.
'True wellness starts from within,' says Gloria. 'It's not just about what you eat or how much you exercise; it's about emotional balance, family connection, and spiritual well-being. When peace and love are within reach, healing begins.'
Resilience and a Purposeful Path
Gloria's journey to founding Amani Upendo Wellness wasn't an easy one. Overcoming personal challenges and breaking free from the limitations imposed by others has shaped her understanding of what true healing looks like. She transformed pain into strength, building a wellness movement dedicated to helping others do the same.
Rather than focus on a quick fix, Gloria emphasizes long-term, sustainable wellness. 'It's about being seen and heard, about stepping into your power and living your truth. I want people to understand that peace and love are always available, no matter their circumstances,' she says.
A Holistic Approach to Healing
Amani Upendo Wellness stands out from other wellness programs by recognizing the multidimensional nature of true healing. Gloria's coaching approach incorporates not just physical health but also emotional well-being and familial harmony. From individuals seeking personal healing to families navigating tough transitions, the program focuses on holistic support.
The wellness company has also become a go-to for family-focused healing, offering resources such as food drives and Bible donations. Over the years, Amani Upendo Wellness has made an impact in the community, having helped people reclaim their health and find emotional peace in the process.
One of the most remarkable aspects of Gloria's outreach is the healing that takes place in the most unexpected of settings. No cameras, no publicity stunts—just people experiencing real change. 'We've had families share their stories of healing, some even getting out of their wheelchairs, all without fanfare,' Gloria shares. 'Healing is a personal, powerful journey.'
Empowering Families Through Community Outreach
Amani Upendo Wellness is not just about individual coaching. The company is deeply committed to community outreach, organizing local events where people can come together in love and healing. Whether it's through family bonding events or acts of kindness like food donations, Gloria's organization provides not just resources, but hope.
There's nothing more powerful than seeing families come together in love,' says Gloria. 'When people heal together, they grow stronger together.' You can check out the App and join Amani Upendo Wellness' Journey here: Amani Upendo Wellness App
Supporting Families with Resources and Tools
Alongside coaching services, Amani Upendo Wellness offers families essential tools to navigate the complexities of modern life. For example, the company has compiled a list of resources offering free products for parents, especially mothers. These resources are designed to alleviate some of the burdens that families face while fostering greater organization and well-being.
From baby supplies to parenting tips, Amani Upendo Wellness is an advocate for supporting families in every aspect of life. Resources such as Huggies, Enfamil, Similac, and BabyBox Canada provide tangible assistance, helping families with everything from baby care to financial relief.
Here are some recent resources for free items available to parents:
Transforming Lives: The Power of Personal and Family Healing
Amani Upendo Wellness isn't just a wellness company—it's a movement. Gloria's commitment to healing is reflected in the company's work, whether it's through one-on-one coaching or its wide-reaching community programs. Through every interaction, Gloria and her team are building and healing families, creating spaces where peace, love, and wellness are no longer distant ideals, but everyday realities.
For those seeking a deeper, more sustainable form of wellness, Amani Upendo Wellness offers more than just services—it offers a life-changing experience that begins with healing from within.
Gloria's journey is far from over, and her mission to bring peace and love into every corner of the world continues to grow stronger. 'I want to show the world that peace and love are always available,' she concludes.
About Amani Upendo Wellness
Founded by Gloria, Amani Upendo Wellness is a transformative wellness company focused on helping individuals and families reclaim their stories and heal holistically. Through trauma-informed coaching and community-driven outreach programs, Amani Upendo Wellness empowers people to find strength, peace, and love in their personal and family lives. The company's mission is clear: wellness begins within, and it can be a transformative force for individuals and their communities.
Media Contact
Gloria
Founder & Wellness Coach, Amani Upendo Wellness
Email: [email protected]
Contact Info:
Name: Gloria
Email: Send Email
Organization: Amani Upendo Wellness
Website: http://www.amaniupendowellness.com
Release ID: 89163465
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound
By Maggie Fick and Bhanvi Satija SEATTLE (Reuters) -U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. U.S. list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4% after 72 weeks in a trial. That compares with weight loss of 15% for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21%. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is "probably going to come on par with the current drugs today or slightly lower," Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. GROWING CASH PAY U.S. doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40% of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce U.S. prices. Novo declined to comment on pricing, pointing to August 6 comments by David Moore, its U.S. operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. MANUFACTURING VOLUME A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the U.S. market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. "It's all about scale and pricing," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. "Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy," Andersen added. Sign in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH
WESTBOROUGH, Mass., Aug. 18, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening their aligned efforts to combat steatotic liver disease, following the U.S. Food and Drug Administration's approval of Wegovy® (semaglutide) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The approval marks a significant milestone as the first GLP-1 therapy approved for MASH, expanding treatment options for patients and providers. "We congratulate Novo Nordisk on this landmark achievement for patients with MASH," says Jon Gingrich, CEO of Echosens North America. "Echosens is proud to serve as a trusted partner to Novo Nordisk, supporting earlier diagnosis, greater access to care, and improved outcomes for patients. As treatment options expand, so does the need for reliable point-of-care tests to identify steatotic liver disease earlier and to monitor treatment response with precision. FibroScan plays a critical role in enabling timely access to MASH treatment by helping providers document medical necessity and guide clinical decisions. We're honored to have FibroScan recognized as the key non-invasive diagnostic solution, and we're excited to grow our strategic partnership so more people can get the care they deserve." MASH affects approximately 1 in 20 people, yet it is estimated that 9 out of 10 cases are undiagnosed, highlighting the need for scalable, non‑invasive tools (NITs) to screen and support ongoing care. MASH is driven by fat accumulation and inflammation in the liver, which may advance to scarring, cirrhosis, and ultimately liver failure if left untreated. Steatotic liver disease also doubles patients' risk of heart attack or stroke and triples the risk of developing diabetes. FibroScan, Echosens' point‑of‑care diagnostic system, uniquely delivers vibration‑controlled transient elastography (VCTE™)—a proprietary, clinically validated technology—to non-invasively assess liver stiffness (fibrosis) and steatosis (fat accumulation) in an exam that takes as little as four minutes. FibroScan exams are widely covered by insurance, used across hepatology, gastroenterology, endocrinology, obesity medicine, and primary care, and are efficient and cost-effective for monitoring treatment response. FibroScan is a key NIT in Novo Nordisk's ongoing ESSENCE trial. It is used to screen patients for enrollment and to measure secondary endpoints related to NITs. At 72 weeks, patients showed improvements in both CAP™ score (a measure of steatosis) and LSM by VCTE™ (an assessment of fibrosis) compared to placebo. These results further establish FibroScan as the leading point-of-care NIT capable of both identifying and monitoring patients appropriate for treatment with semaglutide. Echosens and Novo Nordisk share an ambition of doubling diagnostic rates for people living with advanced to severe MASH by 2027—a goal that requires continued investment in education, awareness, and access to scalable, non-invasive diagnostics. With treatment options expanding and the need for early detection more urgent than ever, both organizations remain firmly committed to improving how MASH is identified and managed. About Echosens Pioneer in its field, Echosens, significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by more than 5,384 peer-reviewed publications and 218 international guidelines. Echosens has made FibroScan® available in over 127 countries, enabling millions of liver examinations worldwide. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. View original content to download multimedia: SOURCE Echosens
Yahoo
5 minutes ago
- Yahoo
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free survival and overall survival IMvigor011 is the first prospective phase III study in muscle-invasive bladder cancer to read out that uses a personalized, ctDNA MRD*-guided approach AUSTIN, Texas, August 18, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 utilizes the Signatera ctDNA test in patients with MIBC to detect molecular residual disease (MRD) in the bloodstream after surgery and predict who will benefit from adjuvant treatment with the cancer immunotherapy atezolizumab (Tecentriq®). Approximately 760 patients were enrolled in the surveillance phase of the trial and underwent serial Signatera testing for up to 12 months post surgery. Patients were randomized to treatment with atezolizumab or placebo if they tested Signatera-positive and remained free of cancer recurrence on imaging with treatment administered every 4 weeks for 12 cycles or up to one year. Patients who consistently tested Signatera-negative were not randomized to treatment but continued to be followed up with radiographic imaging and ctDNA MRD testing. Topline results from IMvigor011 demonstrated a statistically significant and clinically meaningful improvement in disease-free survival and overall survival for Signatera-positive patients treated with atezolizumab. Natera expects trial data to be presented at an upcoming medical conference. "The results of IMvigor011 are very significant, opening the door for a new treatment paradigm for bladder cancer patients who are positive for recurrence on a molecular level but have no evidence of disease on imaging," said Professor Thomas Powles, MBBS, MRCP, M.D., lead principal investigator of the study; Barts Cancer Institute QMUL. "We look forward to presenting the positive results later this year." "Importantly, IMvigor011 could change how resectable bladder cancer is managed for the tens of thousands of patients diagnosed with MIBC each year," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. Natera will finalize its premarket approval application to the U.S. Food and Drug Administration for Signatera as a companion diagnostic for the selection of patients with MIBC to be treated with atezolizumab after cystectomy. In addition to the topline result released today, a preliminary analysis of Signatera-negative patients from IMvigor011 was presented at the European Association of Urology in April 2024. The data highlighted that post-operative patients who remain Signatera-negative on serial testing had excellent outcomes without adjuvant treatment. The analysis showed that 171 patients who remained Signatera-negative during the surveillance window had overall survival rates of 100% at 12 months and 98% at 18 months, and disease-free survival rates of 92% at 12 months and 88% at 18 months after surgery. NotesTecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.*ctDNA MRD = circulating tumor DNA molecular residual disease About NateraNatera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking StatementsAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
